2 research outputs found
The Discovery of Novel Potent <i>trans</i>-3,4-Disubstituted Pyrrolidine Inhibitors of the Human Aspartic Protease Renin from in Silico Three-Dimensional (3D) Pharmacophore Searches
The
small-molecule <i>trans</i>-3,4-disubstituted pyrrolidine <b>6</b> was identified from in silico three-dimensional (3D) pharmacophore
searches based on known X-ray structures of renin–inhibitor
complexes and demonstrated to be a weakly active inhibitor of the
human enzyme. The unexpected binding mode of the more potent enantiomer
(3<i>S</i>,4<i>S</i>)-<b>6a</b> in an extended
conformation spanning the nonprime and S1′ pockets of the recombinant
human (rh)-renin active site was elucidated by X-ray crystallography.
Initial structure–activity relationship work focused on modifications
of the hydrophobic diphenylamine portion positioned in S1 and extending
toward the S2 pocket. Replacement with an optimized P3–P1 pharmacophore
interacting to the nonsubstrate S3<sup>sp</sup> cavity eventually
resulted in significantly improved in vitro potency and selectivity.
The prototype analogue (3<i>S</i>,4<i>S</i>)-<b>12a</b> of this new class of direct renin inhibitors exerted blood
pressure lowering effects in a hypertensive double-transgenic rat
model after oral administration
Structure-Based Design of Substituted Piperidines as a New Class of Highly Efficacious Oral Direct Renin Inhibitors
A <i>cis-</i>configured
3,5-disubstituted piperidine direct renin inhibitor, (<i>syn</i>,<i>rac</i>)-<b>1</b>, was discovered as a high-throughput
screening hit from a target-family tailored library. Optimization
of both the prime and the nonprime site residues flanking the central
piperidine transition-state surrogate resulted in analogues with improved
potency and pharmacokinetic (PK) properties, culminating in the identification
of the 4-hydroxy-3,5-substituted piperidine <b>31</b>. This
compound showed high <i>in vitro</i> potency toward human
renin with excellent off-target selectivity, 60% oral bioavailability
in rat, and dose-dependent blood pressure lowering effects in the
double-transgenic rat model